(3) Existing Policies. The proposed 4.0mg folic acid supplementation
in the trial armhas been recommended forwomen
with a previous pregnancy complicated by NTDs by the
federal government of Canada [37]. The recent recommendations
by the Society for Obstetricians and Gynecologists
of Canada (SOGC) are even more liberal in terms of dosage
(5.0 mg instead of 4.0 mg) and target population (including
women with other risk profiles such as epilepsy or family
history or high risk ethnic group or women without obvious
increased risk but with poor compliance to life-style changes
for healthy pregnancy) for high dose supplementation [38].